ALX Oncology (ALXO) Tmuɣli n wazal
Ṛṛbem n lḥedd$1.31Yettwalemmaḍ 25 Sep 2026 19:59 UTC
Beddel-3.68%
Asnulfu n AI: ALXO
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
ALX Oncology Holdings Inc. operates as a clinical-stage immuno-oncology company. The company focuses on helping patients fight cancer by developing treatments that bridge the innate and adaptive immune systems.
